SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion

kann man die noch handeln? vermutlich ist der Spread dann schon 25%…

Ich hoffe Adler hat heute bei seinem Top Tip 2020 (bald 3-stllg) Mologen nachgelegt. Heute plus 25% 😂😎

Ich hoffe Adler hat heute bei seinem Top Tip 2020 (bald 3-stllg) Mologen nachgelegt. Heute plus 25% 😂😎

Was? War nun doch alles nur aufgepusht und mist? Doch alles Lug und Betrug? Was machen jetzt die Leute mit der mrna Infusion im Arm? 😅🤦‍♂️

Hat Sorrento noch nicht begriffen das Corona vorbei ist und eigentlich nie richtig da war ? Selbst Pfizer gibt öffentlich zu das ihr Medikamente ( Spritzen ) nicht gegen Corona geholfen haben aber Millionen haben sich den scheiß spritzen lassen 🤦‍♂️

Und 1 Nick mehr vom Clown 🤡

Wahnsinn.... was Die alles in der Pipeline haben..?? Nur am statt zu schreiben entwickelt... Sollten sie besser schrieben.... Versuchen zu entwickeln.... Bis jetzt doch garnichts auf die Reihe bekommen...!! Das ist doch nur mal wieder so ein bezahlter bericht von Ji um die Anleger ein bisschen bei Laune zu halten...!!

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.